These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18393850)

  • 1. Biopharmaceutics, pharmacokinetics and pharmacodynamics of antituberculosis drugs.
    Budha NR; Lee RE; Meibohm B
    Curr Med Chem; 2008; 15(8):809-25. PubMed ID: 18393850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects.
    Yew WW
    Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.
    Gumbo T; Pasipanodya JG; Nuermberger E; Romero K; Hanna D
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S18-24. PubMed ID: 26224768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents.
    Keri RS; Sasidhar BS; Nagaraja BM; Santos MA
    Eur J Med Chem; 2015 Jul; 100():257-69. PubMed ID: 26112067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.
    Gumbo T; Angulo-Barturen I; Ferrer-Bazaga S
    J Infect Dis; 2015 Jun; 211 Suppl 3():S96-S106. PubMed ID: 26009618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
    Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
    Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic investigation of resistance via drug-inactivating enzymes in Mycobacterium tuberculosis.
    Kashyap A; Singh PK; Silakari O
    Drug Metab Rev; 2018 Nov; 50(4):448-465. PubMed ID: 30343607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.
    Pasipanodya J; Gumbo T
    Antimicrob Agents Chemother; 2011 Jan; 55(1):24-34. PubMed ID: 20937778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach.
    Pranger AD; Alffenaar JW; Aarnoutse RE
    Curr Pharm Des; 2011; 17(27):2900-30. PubMed ID: 21834759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The resumption of consumption -- a review on tuberculosis.
    Ducati RG; Ruffino-Netto A; Basso LA; Santos DS
    Mem Inst Oswaldo Cruz; 2006 Nov; 101(7):697-714. PubMed ID: 17160276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming drug resistance for tuberculosis.
    Poce G; Biava M
    Future Microbiol; 2015; 10(11):1735-41. PubMed ID: 26516679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of SKLB-TB1001, a Potent Antituberculosis Agent, in Animals.
    Xiong L; Gao C; Shi YJ; Tao X; Peng CT; Rong J; Liu KL; Lei Q; Zhang YW; Wang NY; Yu LT
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug targets exploited in Mycobacterium tuberculosis: Pitfalls and promises on the horizon.
    Bhat ZS; Rather MA; Maqbool M; Ahmad Z
    Biomed Pharmacother; 2018 Jul; 103():1733-1747. PubMed ID: 29864964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extensively drug-resistant tuberculosis in the United States, 1993-2007.
    Shah NS; Pratt R; Armstrong L; Robison V; Castro KG; Cegielski JP
    JAMA; 2008 Nov; 300(18):2153-60. PubMed ID: 19001626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB.
    Vaddady PK; Lee RE; Meibohm B
    Future Med Chem; 2010 Aug; 2(8):1355-69. PubMed ID: 21359155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis.
    Alsaad N; Dijkstra JA; Akkerman OW; de Lange WC; van Soolingen D; Kosterink JG; van der Werf TS; Alffenaar JW
    Antimicrob Agents Chemother; 2016 Jul; 60(7):3942-7. PubMed ID: 27067336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.